Barclays PLC Purchases 56,110 Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX)

Barclays PLC boosted its holdings in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) by 18.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 352,494 shares of the company’s stock after buying an additional 56,110 shares during the period. Barclays PLC owned approximately 0.11% of Amneal Pharmaceuticals worth $2,792,000 as of its most recent SEC filing.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. JPMorgan Chase & Co. grew its holdings in shares of Amneal Pharmaceuticals by 149.7% during the third quarter. JPMorgan Chase & Co. now owns 1,297,094 shares of the company’s stock worth $10,792,000 after purchasing an additional 777,568 shares in the last quarter. China Universal Asset Management Co. Ltd. bought a new position in shares of Amneal Pharmaceuticals in the 4th quarter worth $520,000. Amundi purchased a new stake in shares of Amneal Pharmaceuticals during the 4th quarter valued at $256,000. Franklin Resources Inc. lifted its holdings in shares of Amneal Pharmaceuticals by 4.9% during the 3rd quarter. Franklin Resources Inc. now owns 89,887 shares of the company’s stock worth $778,000 after acquiring an additional 4,178 shares during the last quarter. Finally, Entropy Technologies LP purchased a new position in Amneal Pharmaceuticals in the fourth quarter worth $259,000. 31.82% of the stock is currently owned by hedge funds and other institutional investors.

Insider Buying and Selling at Amneal Pharmaceuticals

In related news, Director Gautam Patel sold 80,000 shares of the business’s stock in a transaction dated Monday, March 3rd. The shares were sold at an average price of $8.90, for a total transaction of $712,000.00. Following the transaction, the director now owns 1,808,886 shares in the company, valued at $16,099,085.40. The trade was a 4.24 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Tushar Bhikhubhai Patel sold 5,000,000 shares of the firm’s stock in a transaction dated Friday, March 14th. The stock was sold at an average price of $8.35, for a total transaction of $41,750,000.00. Following the completion of the sale, the insider now owns 48,578,209 shares of the company’s stock, valued at $405,628,045.15. This trade represents a 9.33 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 5,160,000 shares of company stock valued at $43,113,200 in the last 90 days. Insiders own 26.56% of the company’s stock.

Analysts Set New Price Targets

Several brokerages have issued reports on AMRX. Barclays lifted their price target on Amneal Pharmaceuticals from $10.00 to $11.00 and gave the stock an “overweight” rating in a research note on Monday, March 3rd. JPMorgan Chase & Co. upgraded Amneal Pharmaceuticals from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $9.00 to $12.00 in a research report on Monday, February 24th. Six research analysts have rated the stock with a buy rating, According to MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $10.80.

Amneal Pharmaceuticals Stock Performance

Shares of AMRX stock opened at $7.75 on Wednesday. The company has a market capitalization of $2.40 billion, a P/E ratio of -11.40 and a beta of 1.06. Amneal Pharmaceuticals, Inc. has a fifty-two week low of $5.81 and a fifty-two week high of $9.48. The stock has a 50 day moving average price of $8.05 and a two-hundred day moving average price of $8.18.

Amneal Pharmaceuticals (NASDAQ:AMRX) last posted its quarterly earnings results on Friday, February 28th. The company reported $0.12 EPS for the quarter, missing analysts’ consensus estimates of $0.15 by ($0.03). The firm had revenue of $730.52 million for the quarter, compared to the consensus estimate of $708.21 million. Amneal Pharmaceuticals had a negative net margin of 6.88% and a negative return on equity of 346.26%. During the same quarter in the prior year, the company earned $0.14 earnings per share. As a group, equities analysts predict that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current year.

Amneal Pharmaceuticals Profile

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.